Systemic Sclerosis - Scleroderma (CREST) Flashcards
What is scleroderma?
A multi-system disease characterised by skin hardening and Raynaud’s phenomenon.
How is systemic scleroderma different from localised scleroderma?
Distinct from localised scleroderma such as morphea, that do not involve internal organ disease and are rarely associated with vasospasm (Raynaud’s
phenomenon)
Explain the pathophysiology behind systemic sclerosis.
- Autoimmune dysfunction causes overproduction of collagen.
- T cells accumulate in skin and secrete cytokines, which stimulate collagen deposition (skin hardening) and stimulate fibroblasts.
- Also inflammation & auto-antibody production.
Scleroderma (skin fibrosis) + vascular disease.
What are the 2 types of systemic scleroderma? Which one is more common?
- Limited cutaneous scleroderma (LcSSc)/CREST SYNDROME - 70% cases
- Diffuse cutaneous scleroderma (DcSSc) - 30% cases
What parts of the body is skin involvement limited to in LcSSc?
Hands, feet and face
What parts of the body are affected by diffuse systemic sclerosis?
Diffuse skin involvement.
Heart, lungs, GI tract and kidneys all involved.
What feature is present in almost 100% of cases of systemic scleroderma?
Raynaud’s phenomenon
Give 5 signs of limited scleroderma.
- Calcinosis.
- Raynaud’s phenomenon.
- Oesophageal reflux.
- Sclerodactyly (thickening and tightening of the skin).
- Telangectasia (visible small red blood vessels - ‘spider veins’)
- Pulmonary arterial hypertension.
Give 4 signs of diffuse scleroderma.
- Proximal scleroderma.
- Pulmonary fibrosis.
- Bowel involvement.
- Myositis.
- Renal crisis.
Outline the investigations done in systemic sclerosis (scleroderma).
- Bloods - Normochromic, normocytic anaemia
- Bloods- autoantibodies
- Urinalysis
- Imaging - CXR, Hands X-ray, Barium swallow, high-resolution CT
What autoantibodies might you find on investigation of a patient with systemic sclerosis?
ANA, RhF, ACA, anti-topoisomerase, anti-RNA polymerase
Autoantibodies:
- Limited cutaneous scleroderma/CREST:
* Speckled, Nucleolar or ANTI-CENTROMERE ANTIBODIES (ACAs) - 70% cases
- Diffuse cutaneous scleroderma:
- Anti-topoisomerase-1 antibodies (anti-Scl-70) - 30% cases
- Anti-RNA polymerase - 20-25% cases
- Rheumatoid factor is positive in 30%
- Anti-nuclear antibodies (ANA) is positive in 95%
Describe the management of systemic sclerosis (scleroderma).
- Raynaud’s
* Hand warmers
* Oral vasodilators
- Calcium channel blocker e.g. ORAL NIFEDIPINE
- Endothelin receptor antagonist e.g. ORAL BOSENTAN - GORD: PPI’s.
- Annual Echo and pulmonary function tests to monitor arterial pulmonary pressure.
- ACEi to prevent renal crisis.
- Pulmonary fibrosis:
* Immunosuppressant e.g. IV CYCLOPHOSPHAMIDE
* ORAL PREDNISOLONE